Avelumab monotherapy as first-line or second-line treatment in patients with metastatic renal cell carcinoma: phase Ib results from the JAVELIN Solid Tumor trial

ConclusionAvelumab showed clinical activity and a manageable safety profile in both the 1  L and 2 L treatment setting in patients with mRCC. These data support the use of avelumab in combination with other agents in mRCC.Trial registrationClinicalTrials.gov:NCT01772004; registered 21 January, 2013.
Source: Journal for Immunotherapy of Cancer - Category: Cancer & Oncology Source Type: research